Group 1 - The company, Shanghai Aladdin Biochemical Technology Co., Ltd., plans to invest in Shanghai Yamei Biomedical Technology Co., Ltd. through capital increase and share acquisition, with a total investment of 41.17 million RMB [2] - The investment will be executed in two steps: first, a capital increase of 24.7 million RMB for a 15% stake at a valuation of 140 million RMB; second, acquiring a 10% stake from existing shareholders for 16.47 million RMB [2] - Upon completion of the investment, the company will hold a total of 25% equity in Yamei Biomedical [2] Group 2 - Yamei Biomedical has completed its business registration, with a registered capital of 1.433154 million RMB and established on March 18, 2019 [3] - The company operates in various fields including technology services, health consulting, cell technology research, and biomedical engineering [3] - The legal representative of Yamei Biomedical is Wu Jun, and it is classified as a limited liability company [3]
上海阿拉丁生化科技股份有限公司关于对外投资上海雅酶生物医药科技有限公司的进展暨完成工商登记的公告